All In Biotech

Drug Trial Radar · NCT05415072

A Phase I/II Study of DYP688 in Patients With Metastatic Uveal Melanoma and Other GNAQ/11 Mutant Melanomas

A Phase I/II, Multi-center, Open Label Study of DYP688 in Patients With Metastatic Uveal Melanoma (MUM) and Other GNAQ/11 Mutant Melanomas

Last checked: Nov 19, 2026Latest source record: Jul 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

66

Actual

Start

Jul 4, 2022

Primary completion

Oct 1, 2027

Study completion Oct 1, 2027

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Jun 10, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 100 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a FIH, phase I/II, open label, multi-center study of DYP688 as a single agent. The purpose of this study is to characterize the safety, tolerability, and anti-tumor activity of DYP688 as a single agent in patients with metastatic uveal melanoma (MUM) and other melanomas harboring GNAQ/11 mutations.

Conditions

  • Metastatic Uveal Melanoma

Interventions

  • DYP688Drug

    Single agent DYP688

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase I (Dose Escalation): Incidence and severity of dose limiting toxicities (DLTs) during the first 28 days of treatment.Time frame: 28 days
  2. Phase I (Dose Escalation): Incidence and severity of adverse events (AEs) and serious adverse events (SAEs)Time frame: 9 months
  3. Phase I (Dose Escalation): Frequency of dose interruptions, reductions, and discontinuationsTime frame: 9 months
  4. Phase II: Overall Response rate (ORR) per RECIST 1.1Time frame: 17 months

Locations

11 sites in 7 countries. Site status is shown where the registry gives one.

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Columbia University Medical Center

    New York, New York

  • Memorial Sloane Ketterin Cancer Ctr

    New York, New York

  • Novartis Investigative Site

    Westmead, New South Wales, Australia

  • Novartis Investigative Site

    Melbourne, Victoria, Australia

  • Novartis Investigative Site

    Paris, France

  • Novartis Investigative Site

    Essen, Germany

  • Novartis Investigative Site

    Heidelberg, Germany

  • Novartis Investigative Site

    Leiden, South Holland, Netherlands

  • Novartis Investigative Site

    Madrid, Spain

  • Novartis Investigative Site

    Zurich, Switzerland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.